The case for intensive statin therapy after acute coronary syndromes.

No abstract is available for this paper.

• Publication year

  2005

• Venue

  American Journal of Cardiology

• Publication date

  2005-09-05

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/J.AMJCARD.2005.06.026PMID 16126023
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Atorvastatin has an important acute anti-inflammatory effect in patients with acute coronary syndrome: results of a randomized, double-blind, placebo-controlled study.

  2005cited by this paper
• High-density lipoprotein, but not low-density lipoprotein cholesterol levels influence short-term prognosis after acute coronary syndrome: results from the MIRACL trial.

  2005cited by this paper
• Evidence for anti-inflammatory activity of statins and PPARalpha activators in human C-reactive protein transgenic mice in vivo and in cultured human hepatocytes in vitro.

  2004cited by this paper
• Early Intensive vs a Delayed Conservative Simvastatin Strategy in Patients With Acute Coronary Syndromes

  2004cited by this paper
• Effect of Atorvastatin on Risk of Recurrent Cardiovascular Events After an Acute Coronary Syndrome Associated With High Soluble CD40 Ligand in the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study

  2004cited by this paper
• Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines.

  2004cited by this paper
• Effect of pravastatin compared with placebo initiated within 24 hours of onset of acute myocardial infarction or unstable angina: the Pravastatin in Acute Coronary Treatment (PACT) trial.

  2004cited by this paper
• Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial.

  2004cited by this paper
• Early Statin Treatment in Patients With Acute Coronary Syndrome: Demonstration of the Beneficial Effect on Atherosclerotic Lesions by Serial Volumetric Intravascular Ultrasound Analysis During Half a Year After Coronary Event: The ESTABLISH Study

  2004cited by this paper
• Impact of concurrent medication use on statin adherence and refill persistence.

  2004cited by this paper
• Safety of atorvastatin derived from analysis of 44 completed trials in 9,416 patients.

  2003cited by this paper
• High-Dose Atorvastatin Enhances the Decline in Inflammatory Markers in Patients With Acute Coronary Syndromes in the MIRACL Study

  2003cited by this paper
• Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial.

  2003cited by this paper
• Soluble CD40L: Risk Prediction After Acute Coronary Syndromes

  2003cited by this paper
• C-reactive protein and atherothrombosis—Beyond a biomarker: an actual partaker of lesion formation

  2003cited by this paper
• Análisis crítico de un artículo Las estatinas reducen la morbi-mortalidad en pacientes de alto riesgo cardiovascular: Heart Protection Study Collaborative Group. (HPS). Lancet 2002; 360: 7-22.

  2003cited by this paper
• C-reactive protein and atherothrombosis--beyond a biomarker: an actual partaker of lesion formation.

  2003cited by this paper
• MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial.

  2002cited by this paper
• Effects of Atorvastatin on Stroke in Patients With Unstable Angina or Non-Q-Wave Myocardial Infarction: A Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Substudy

  2002cited by this paper
• Simvastatin Lowers C-Reactive Protein Within 14 Days: An Effect Independent of Low-Density Lipoprotein Cholesterol Reduction

  2002cited by this paper
• MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Commentary

  2002cited by this paper
• Early statin initiation and outcomes in patients with acute coronary syndromes.

  2002cited by this paper
• Effect of fluvastatin on ischaemia following acute myocardial infarction: a randomized trial.

  2002cited by this paper
• Use of Lipid-Lowering Medications at Discharge in Patients With Acute Myocardial Infarction: Data From the National Registry of Myocardial Infarction 3

  2001cited by this paper
• Early statin treatment following acute myocardial infarction and 1-year survival.

  2001cited by this paper
• Effect of lipid-lowering therapy on early mortality after acute coronary syndromes: an observational study.

  2001cited by this paper
• Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.

  2001cited by this paper
• Increase in Circulating Endothelial Progenitor Cells by Statin Therapy in Patients With Stable Coronary Artery Disease

  2001cited by this paper
• Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial.

  2001cited by this paper
• Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban.

  2001cited by this paper
• Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes. The MIRACL study.

  2001cited by this paper
• Reduction of Stroke Events With Pravastatin: The Prospective Pravastatin Pooling (PPP) Project

  2001cited by this paper
• Effect of cholesterol-lowering therapy on coronary endothelial vasomotor function in patients with coronary artery disease.

  2000cited by this paper
• Inhibition of tissue-factor-mediated thrombin generation by simvastatin.

  2000cited by this paper
• Invasive compared with non-invasive treatment in unstable coronary-artery disease: FRISC II prospective randomised multicentre study

  1999cited by this paper
• Invasive compared with non-invasive treatment in unstable coronary-artery disease: FRISC II prospective randomised multicentre study. FRagmin and Fast Revascularisation during InStability in Coronary artery disease Investigators.

  1999cited by this paper
• Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors.

  1998cited by this paper
• Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction.

  1998cited by this paper
• Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels.

  1998cited by this paper
• Effects of lipids and lipoproteins on thrombosis and rheology.

  1998cited by this paper
• Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month.

  1997cited by this paper
• Single LDL apheresis improves endothelium-dependent vasodilatation in hypercholesterolemic humans.

  1997cited by this paper
• Low-density lipoproteins inhibit the Na+/H+ antiport in human platelets. A novel mechanism enhancing platelet activity in hypercholesterolemia.

  1997cited by this paper
• The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators.

  1996cited by this paper
• Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease.

  1995cited by this paper
• Hyperlipidemia and coronary disease. Correction of the increased thrombogenic potential with cholesterol reduction.

  1995cited by this paper
• Inhibition of thromboxane biosynthesis and platelet function by simvastatin in type IIa hypercholesterolemia.

  1995cited by this paper
• Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)

  1994cited by this paper
• Vasoreactivity of the Culprit Lesion in Unstable Angina

  1994cited by this paper
• The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina.

  1994cited by this paper
• Macrophage Infiltration in Acute Coronary Syndromes: Implications for Plaque Rupture

  1994cited by this paper
• Relation of the site of acute myocardial infarction to the most severe coronary arterial stenosis at prior angiography.

  1992cited by this paper

• KIF6 gene as a pharmacogenetic marker for lipid-lowering effect in statin treatment

  2018cites this paper
• Activation of the homeostatic intracellular repair response during cardiac surgery.

  2013cites this paper
• Effect of moderate-intensity statin therapy on plaque inflammation in patients with acute coronary syndrome: A prospective interventional study evaluated by 18F-FDG PET/CT of the carotid artery.

  2013cites this paper
• Establishment of basic lipidomics platforms for discovery of lipid biomarkers

  2012cites this paper
• Atorvastatin Efficacy in the Primary and Secondary Prevention of Cardiovascular Events

  2012cites this paper
• The Year in NonST-Segment Elevation Acute Coronary Syndrome

  2011cites this paper
• Metabolic syndrome and outcome in patients with acute myocardial infarction.

  2011cites this paper
• [Motor protein Kinesin-6 and ischemic heart disease].

  2010cites this paper
• Genomics of Myocardial Infarction

  2010cites this paper
• Lipid reduction in acute coronary syndrome: How much, when, and how?

  2009cites this paper
• The year in non-ST-segment elevation acute coronary syndrome.

  2009cites this paper
• CHAPTER 57 – Genomics of Myocardial Infarction

  2009cites this paper
• Approaches to neuroprotective and reperfusion injury therapy.

  2009cites this paper
• CHAPTER 39 – Special Patient Populations: Acute Coronary Syndromes

  2009cites this paper
• Polymorphism in KIF6 gene and benefit from statins after acute coronary syndromes: results from the PROVE IT-TIMI 22 study.

  2008cites this paper
• Epithelial Neutrophil-Activating Peptide (ENA-78), Acute Coronary Syndrome Prognosis, and Modulatory Effect of Statins

  2008cites this paper
• Statins for Surgical Patients

  2008cites this paper
• [Effect of pitavastatin on macrophage cholesterol metabolism].

  2008cites this paper
• NON ST ELEVATION ACUTE CORONARY SYNDROME : CONTEMPORARY MANAGEMENT STRATEGIES

  2008cites this paper
• Does C-reactive protein predict saphenous vein graft patency?

  2007cites this paper
• Statins in elderly patients with acute coronary syndrome: an analysis of dose and class effects in typical practice

  2007cites this paper
• Nitric oxide is a preconditioning mimetic and cardioprotectant and is the basis of many available infarct-sparing strategies.

  2006cites this paper
• Dietary cholesterol and differential monocyte chemoattractant protein-1 gene expression in aorta and liver of apo E-deficient mice.

  2006cites this paper
• Statins in the intensive care unit

  2006cites this paper
• Should all patients receive statins before cardiac surgery: are more data necessary?

  2006cites this paper
• The year in non-ST-segment elevation acute coronary syndromes.

  2006cites this paper
• [Influence of admission glucose level on long-term prognosis in patients with acute coronary syndrome].

  2006cites this paper
• Influencia de la concentración de glucemia en el momento del ingreso en la evolución a largo plazo de los pacientes con síndrome coronario agudo

  2006cites this paper
• Immunomodulation strategies for preventing vascular disease of the brain and heart: workshop summary.

  2006cites this paper
• The year in non-ST-segment elevation acute coronary syndrome.

  2005cites this paper
• Review of primary and secondary prevention trials with lovastatin, pravastatin, and simvastatin.

  2005cites this paper